Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.

Despite the importance and frequency of levodopa-induced dyskinesias, little is known about their causal mechanisms. In this study, electrophysiological single-unit recordings of the neuronal activity of the globus pallidus internalis (GPi), the main basal ganglia output structure, and the globus pallidus externalis (GPe) were recorded continuously in both normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated subhuman primates before and after the administration of three dopamine agonists--apomorphine (a dopaminergic mixed agonist), SKF-38393 (a D1 partial agonist) and piribedil (a D2/D3 agonist)--at doses known to induce dyskinesias in the parkinsonian monkey. Changes in both the firing frequency and the firing pattern were analysed in relation to behavioural modifications. In both the normal and the parkinsonian monkey, the three agonists induced a decrease in the mean firing frequency of GPi neurones, although dyskinesias were induced only in the parkinsonian animals. In this situation, the improvement of parkinsonian motor abnormalities was correlated with the decrease in GPi firing frequency, whereas firing pattern changes were concomitant with the onset of dyskinesias. Moreover, firing frequency seemed to be decreased excessively during dyskinesias. The results indicate that the electrophysiological mechanism of dyskinesia involves an excessive decrease in GPi firing frequency and a modification of the firing pattern. However, the similarity between the induced decrease in firing frequency in normal and parkinsonian animals underlines the need for dopamine depletion in the induction of dyskinesias.

[1]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[2]  D. Surmeier,et al.  Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. , 1998, Advances in pharmacology.

[3]  E. Bézard,et al.  Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey , 2000, Neuroscience Letters.

[4]  M. Inase,et al.  Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements. , 1991, Journal of neurophysiology.

[5]  P. Bédard,et al.  Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys , 1992, Experimental Neurology.

[6]  L. Tremblay,et al.  Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.

[7]  L. Tremblay,et al.  Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.

[8]  J. Vitek,et al.  Burst and oscillation as disparate neuronal properties , 1996, Journal of Neuroscience Methods.

[9]  O. Hassani,et al.  Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study , 1999, Neuroscience.

[10]  B. Levant,et al.  Differential distribution of D3 dopamine receptors in the brains of several mammalian species , 1998, Brain Research.

[11]  R. Roth,et al.  Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .

[12]  B. Bloch,et al.  D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAS in distinct neuronal populations of the dorsal and ventral striatum , 1995, The Journal of comparative neurology.

[13]  F. Calon,et al.  Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis , 1997, Neuroscience.

[14]  E. Bézard,et al.  High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey , 1996, Neuroscience Letters.

[15]  P. Jenner,et al.  The rationale for the use of dopamine agonists in Parkinson's disease , 1995, Neurology.

[16]  G. Robertson,et al.  Pathophysiology of L-dopa-induced dyskinesias. , 1999, Movement Disorders.

[17]  M. Merello,et al.  Apomorphine induces changes in GPi spontaneous outflow in patients with parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[18]  G. E. Alexander,et al.  Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.

[19]  J A Obeso,et al.  Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. , 2000, Annals of neurology.

[20]  P. Bédard,et al.  Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys , 1996, Brain Research.

[21]  R. Desimone,et al.  Internal globus pallidus discharge is nearly suppressed during levodopa‐induced dyskinesias , 1999, Annals of neurology.

[22]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[23]  B. Bloch,et al.  Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation , 1996, Brain Research.

[24]  B Bioulac,et al.  Effects of l-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey , 1998, Brain Research.

[25]  J. Dostrovsky,et al.  Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. , 2000, Annals of neurology.

[26]  GPi Firing rate modification during beginning‐of‐dose motor deterioration following acute administration of apomorphine , 1999, Movement disorders : official journal of the Movement Disorder Society.

[27]  B. Gomez-Mancilla,et al.  Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia? , 1995, Fundamental & clinical pharmacology.

[28]  B Bioulac,et al.  Reversal of Rigidity and Improvement in Motor Performance by Subthalamic High‐frequency Stimulation in MPTP‐treated Monkeys , 1993, The European journal of neuroscience.

[29]  P. Svenningsson,et al.  Dopamine–Adenosine Interactions in the Striatum and the Globus Pallidus: Inhibition of Striatopallidal Neurons through Either D2 or A2A Receptors Enhances D1Receptor-Mediated Effects on c-fos Expression , 1997, The Journal of Neuroscience.

[30]  P. Sokoloff,et al.  Novel dopamine receptors half a decade later. , 1995, Trends in pharmacological sciences.

[31]  H. Akil,et al.  Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization- receptor autoradiographic analysis , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  H. Bergman,et al.  The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. , 1994, Journal of neurophysiology.

[33]  F. Durif Treating and Preventing Levodopa-Induced Dyskinesias , 1999, Drugs & aging.

[34]  M. Woodruff,et al.  Toxin-Induced Models of Neurological Disorders , 1994, Springer US.

[35]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[36]  P. Blanchet,et al.  Dyskinesia and wearing‐off following dopamine D1 agonist treatment in drug‐naive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned primates , 1996, Movement disorders : official journal of the Movement Disorder Society.

[37]  A. Benazzouz,et al.  Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. , 1995, European journal of pharmacology.

[38]  E. Bézard,et al.  Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms , 1999, The European journal of neuroscience.

[39]  S. Iversen,et al.  Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.

[40]  P. Jenner,et al.  An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets , 1996, Movement disorders : official journal of the Movement Disorder Society.

[41]  E. Bézard,et al.  Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental Parkinsonism , 1997, Neuroscience.

[42]  B Bioulac,et al.  Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. , 2000, Journal of neurophysiology.

[43]  E. Bézard,et al.  Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey , 2000, Journal of Neuroscience Methods.

[44]  D. Guehl,et al.  High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. , 1997, Journal of neurosurgery.

[45]  J. Dostrovsky,et al.  Effects of apomorphine on globus pallidus neurons in parkinsonian patients , 1997, Annals of neurology.